Instinct Bio Technical Co. Holdings Inc. Goes Public: What to Watch
Instinct Bio Technical Co. Holdings Inc. (BIOT) is expected to list on NASDAQ on 2026-07-24, but the price range has not been disclosed. This is a SPAC business combination, not a traditional underwritten IPO. The bull case is a vertically integrated regenerative medicine and stem-cell skincare platform; the bear case is that the public story is still light on disclosed financial detail.
Instinct Bio Technical Co. Holdings Inc. (BIOT) is expected to list on NASDAQ on 2026-07-24, but the price range has not been disclosed. This is a SPAC business combination, not a traditional underwritten IPO. The bull case is a vertically integrated regenerative medicine and stem-cell skincare platform; the bear case is that the public story is still light on disclosed financial detail.
Quick Facts
Expected listing date: July 24, 2026
Exchange: NASDAQ
Proposed symbol: BIOT
Status: Expected
Company Overview
Instinct Bio Technical Co. Holdings Inc. describes itself as a vertically integrated holding company spanning “materials science to brands,” with activities in research, sourcing and manufacturing, brands, and investment. Its public materials point to a business built around advanced materials science and regenerative medicine, including stem-cell-derived skincare, medical consulting, and clinic/franchise operations under the GENREVER brand.
The company says it was established in 2024 and is organized through a Cayman Islands holding company structure, with the operating business described in merger materials as a Japanese regenerative medicine and stem cell technology company. The group also highlights an ISO 9001-certified manufacturing facility and a proprietary stem-cell culture medium with “over 380 cytokines and growth factors,” which is the core of its differentiation claim.
BIOT is entering a niche that sits between beauty, wellness, and regenerative medicine. The SEC filing classifies the business under SIC 2844, which covers perfumes, cosmetics and other toilet preparations, while the company’s own narrative leans into anti-aging, stem-cell science, and clinic expansion. That market mix can be attractive because it taps secular demand for premium skincare and wellness, but it also means the company is competing across fragmented categories with no single clean peer set.
Why They're Going Public
This was structured as a business combination with Relativity Acquisition Corp., so the public listing is tied to the merger closing rather than a standard IPO capital raise. The transaction was intended to provide capital for the combined company, but the accessible materials do not include a specific use-of-proceeds table.
What going public unlocks here is mainly scale and visibility. The company gets a U.S. public listing, a broader capital base, and a currency it can use for growth, while also giving investors a way to back a regenerative medicine and stem-cell skincare platform that is trying to combine manufacturing, branding, and clinic distribution under one roof.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The accessible SEC snippets do not surface a clean full income statement for Instinct Bio Technical Co. Holdings Inc., so there are no disclosed revenue, margin, or cash figures I can cite responsibly from the materials provided. The proxy materials do indicate that diligence focused on commercial traction, revenue, business model, key partners, and vendors, which suggests the company had some operating history and customer traction before the merger.
Because the filing excerpts available here do not show the underlying tables, the most important financial takeaway is the absence of hard public numbers in the search results, not a specific trend. For a fresh public investor, that means the key question is not just growth, but whether the company can translate its science-and-brand story into repeatable revenue and a clearer path to profitability once it is public.
Risk Factors
The biggest structural risk is that BIOT is a holding company at the pubco level, so it does not directly conduct operations or generate revenue there. Investors are effectively underwriting the operating subsidiaries and the execution of a cross-border business that spans manufacturing, branding, and clinic coordination. The company also sits in a regulated area tied to regenerative medicine and cosmetics, which raises commercialization and compliance risk even though the full filing risk section was not surfaced in the snippets.
The other key risks are execution and dilution. The transaction was subject to stockholder approval and customary closing conditions, and the sources do not disclose float, total shares offered, or a confirmed lockup for this deal. That leaves shareholders watching for how much stock is actually available, how tightly insiders are locked up, and whether the company can defend its differentiation against larger beauty, wellness, and life-science names with deeper balance sheets and more established distribution.
Comparable Public Companies
The closest public comps are imperfect because BIOT straddles cosmetics, wellness, and biotech. On the beauty side, ELF Beauty (ELF), Coty (COTY), and L’Oréal (OR.PA, LRLCY) are the most obvious reference points. On the life-science or aesthetics side, Revance Therapeutics (RVNC) and Bio-Techne (TECH) are looser comparables, but they help frame the market’s willingness to pay for science-led product stories.
Relative to those names, BIOT looks much earlier and less disclosed. The company has not provided the kind of public revenue scale or margin profile that would let investors compare it cleanly on valuation, so the market will likely focus more on narrative, growth potential, and execution than on near-term multiples. The comp set is mixed rather than uniformly hot: beauty names tend to trade on brand strength and margin durability, while biotech and aesthetics names are more sensitive to pipeline risk and commercialization timing. That makes BIOT’s setup more story-driven than benchmark-driven.
Verdict
The main thing to watch as BIOT prices is whether investors are comfortable backing a public regenerative medicine and stem-cell skincare platform with limited disclosed financial detail. The company has a differentiated narrative: Japanese operating roots, vertical integration, an ISO 9001-certified facility, and a clinic-plus-brand model. But the absence of disclosed pricing, share count, and a clean financial snapshot means the market will have to decide how much of that story is already reflected in the deal structure.
This listing is noteworthy because it comes through a de-SPAC rather than a traditional IPO, and it arrives in a niche that blends beauty, wellness, and regenerative medicine. That gives it a different angle from a standard consumer IPO: the setup favors investors who want exposure to a secular anti-aging and stem-cell theme, but the public debut still needs to prove that the business can scale beyond the narrative. With BIOT first trading on 2026-07-24, the real tell will be how the market prices the combination of science, brand, and execution risk right out of the gate.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
